The global Kaposi’s Sarcoma market is expanding due to the HIV/AIDS prevalence, improved oncology infrastructure, and advancements in targeted and immunotherapeutic drugs. Kaposi’s Sarcoma, a tumor ...

In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4 + ≥50 cells/μL and HIV plasma RNA <200 copies/mL. Pembrolizumab 200 mg ...

Kaposi's sarcoma (KS) is a low-grade vascular neoplasm mediated by the human herpesvirus-8. Only 1 clinical subtype, the endemic/African subtype, commonly affects the pediatric population. Although ...